Dr. Trevor Feinstein, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
1267 Highway 54 W Ste 4200
Fayetteville, GA 30214
Who else practices at this address →
Fayette County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 760
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb)
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
GA license 65768
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Northside Hospital Atlanta, GA
- Piedmont Hospital, Inc Atlanta, GA
- Piedmont Fayette Hospital Fayetteville, GA
- Piedmont Henry Hospital Stockbridge, GA
- Piedmont Newnan Hospital, Inc Newnan, GA
Medical groups
- Piedmont Cancer Institute PC (43 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 760
- Services billed
- 254,069
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 36,360 | 14 |
| Injection, oxaliplatin, 0.5 mg | 18,866 | 17 |
| Injection, pembrolizumab, 1 mg | 15,200 | 25 |
| Injection, denosumab, 1 mg | 12,480 | 70 |
| Injection, paclitaxel, 1 mg | 9,128 | 14 |
| Injection, ferric derisomaltose, 10 mg | 5,300 | 47 |
| Injection, dexamethasone sodium phosphate, 1 mg | 3,054 | 74 |
| Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | 2,997 | 11 |
| Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg | 2,007 | 11 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,509 | 641 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Fayetteville, GA | 410 |
| Eliquis (apixaban) Other prescribers in Fayetteville, GA | 188 |
| Ondansetron Odt (ondansetron) Other prescribers in Fayetteville, GA | 159 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Fayetteville, GA | 153 |
| Prochlorperazine Maleate Other prescribers in Fayetteville, GA | 114 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Fayetteville, GA | 112 |
| Letrozole Other prescribers in Fayetteville, GA | 106 |
| Potassium Chloride Other prescribers in Fayetteville, GA | 99 |
| Dexamethasone Other prescribers in Fayetteville, GA | 97 |
| Xarelto (rivaroxaban) Other prescribers in Fayetteville, GA | 93 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 105 payments worth $94,610 in total to this clinician.
| Genzyme Corporation | $42,977 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $35,503 |
| Recordati_rare_diseases_inc. | $9,021 |
| Daiichi Sankyo Inc. | $5,979 |
| Gilead Sciences, Inc. | $255 |
| Merck Sharp & Dohme LLC | $228 |
| Regeneron Healthcare Solutions, Inc. | $214 |
| AbbVie Inc. | $176 |
| Compensation for services other than consulting (speaking, faculty) | $66,057 |
|---|---|
| Consulting Fee | $12,596 |
| Travel and Lodging | $7,062 |
| Honoraria | $5,880 |
| Food and Beverage | $3,015 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) WAYRILZ · Immunology | $8,567 |
| Genzyme Corporation Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) WAYRILZ · Immunology | $8,238 |
| Genzyme Corporation Jul 17, 2025 | Compensation for services other than consulting (speaking, faculty) WAYRILZ · Immunology | $6,920 |
| Recordati_rare_diseases_inc. May 9, 2025 | Honoraria ENJAYMO · HEMATOLOGY | $5,880 |
| Genzyme Corporation Sep 13, 2025 | Compensation for services other than consulting (speaking, faculty) WAYRILZ · Immunology | $5,272 |
| AstraZeneca Pharmaceuticals LP Nov 10, 2025 | Compensation for services other than consulting (speaking, faculty) DATROWAY · Oncology Company’s descriptionSpeaker Fee | $4,690 |
| AstraZeneca Pharmaceuticals LP Aug 6, 2025 | Consulting Fee | $4,355 |
| Daiichi Sankyo Inc. Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) DATROWAY · ONCOLOGY | $4,020 |
| AstraZeneca Pharmaceuticals LP Sep 3, 2025 | Compensation for services other than consulting (speaking, faculty) DATROWAY · Oncology Company’s descriptionSpeaker Fee | $3,350 |
| AstraZeneca Pharmaceuticals LP Apr 29, 2025 | Compensation for services other than consulting (speaking, faculty) IMFINZI · Oncology Company’s descriptionSpeaker Fee | $3,350 |
All 48 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Dec 17, 2025 | Travel and Lodging travel to Duluth, GA | $77.00 |
| AstraZeneca Pharmaceuticals LP Dec 16, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $2,010 |
| Genzyme Corporation Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) WAYRILZ · Immunology | $8,238 |
| Genzyme Corporation Nov 20, 2025 | Travel and Lodging WAYRILZ · Immunology · travel to Fort Myers, FL · in-kind | $900 |
| Genzyme Corporation Nov 20, 2025 | Travel and Lodging WAYRILZ · Immunology · travel to Fort Myers, FL · in-kind | $567 |
| Genzyme Corporation Nov 20, 2025 | Travel and Lodging WAYRILZ · Immunology · travel to Fort Myers, FL · in-kind | $140 |
| Genzyme Corporation Nov 20, 2025 | Travel and Lodging WAYRILZ · Immunology · travel to Fort Myers, FL | $46.75 |
| Genzyme Corporation Nov 20, 2025 | Travel and Lodging WAYRILZ · Immunology · travel to Fort Myers, FL | $30.00 |
| AstraZeneca Pharmaceuticals LP Nov 13, 2025 | Travel and Lodging DATROWAY · Oncology · travel to Alpharetta, GA | $77.00 |
| AstraZeneca Pharmaceuticals LP Nov 10, 2025 | Compensation for services other than consulting (speaking, faculty) DATROWAY · Oncology Company’s descriptionSpeaker Fee | $4,690 |
| AstraZeneca Pharmaceuticals LP Nov 10, 2025 | Compensation for services other than consulting (speaking, faculty) DATROWAY · Oncology Company’s descriptionSpeaker Fee | $2,010 |
| AstraZeneca Pharmaceuticals LP Nov 10, 2025 | Compensation for services other than consulting (speaking, faculty) DATROWAY · Oncology Company’s descriptionSpeaker Fee | $2,010 |
| AstraZeneca Pharmaceuticals LP Nov 6, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $250 |
| AstraZeneca Pharmaceuticals LP Oct 31, 2025 | Compensation for services other than consulting (speaking, faculty) DATROWAY · Oncology Company’s descriptionSpeaker Fee | $2,010 |
| Genzyme Corporation Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) WAYRILZ · Immunology | $8,567 |
| Genzyme Corporation Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) WAYRILZ · Immunology | $3,295 |
| Genzyme Corporation Oct 14, 2025 | Travel and Lodging WAYRILZ · Immunology · travel to Norwood, MA · in-kind | $867 |
| Genzyme Corporation Oct 14, 2025 | Travel and Lodging WAYRILZ · Immunology · travel to Norwood, MA · in-kind | $590 |
| Genzyme Corporation Oct 14, 2025 | Travel and Lodging WAYRILZ · Immunology · travel to Norwood, MA · in-kind | $298 |
| Genzyme Corporation Oct 14, 2025 | Travel and Lodging WAYRILZ · Immunology · travel to Norwood, MA | $60.00 |
| Genzyme Corporation Oct 14, 2025 | Travel and Lodging WAYRILZ · Immunology · travel to Norwood, MA | $23.91 |
| Daiichi Sankyo Inc. Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) DATROWAY · ONCOLOGY | $4,020 |
| Recordati_rare_diseases_inc. Sep 26, 2025 | Consulting Fee ENJAYMO · HEMATOLOGY | $2,205 |
| AstraZeneca Pharmaceuticals LP Sep 25, 2025 | Compensation for services other than consulting (speaking, faculty) DATROWAY · Oncology Company’s descriptionSpeaker Fee | $2,010 |
| Daiichi Sankyo Inc. Sep 25, 2025 | Travel and Lodging DATROWAY · ONCOLOGY · travel to DULUTH, GA · in-kind | $718 |
| AstraZeneca Pharmaceuticals LP Sep 24, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $600 |
| AstraZeneca Pharmaceuticals LP Sep 16, 2025 | Consulting Fee | $1,340 |
| Genzyme Corporation Sep 13, 2025 | Compensation for services other than consulting (speaking, faculty) WAYRILZ · Immunology | $5,272 |
| Daiichi Sankyo Inc. Sep 9, 2025 | Travel and Lodging DATROWAY · ONCOLOGY · travel to AUGUSTA, GA · in-kind | $891 |
| AstraZeneca Pharmaceuticals LP Sep 3, 2025 | Compensation for services other than consulting (speaking, faculty) DATROWAY · Oncology Company’s descriptionSpeaker Fee | $3,350 |
| AstraZeneca Pharmaceuticals LP Aug 21, 2025 | Compensation for services other than consulting (speaking, faculty) DATROWAY · Oncology Company’s descriptionSpeaker Fee | $600 |
| AstraZeneca Pharmaceuticals LP Aug 6, 2025 | Consulting Fee | $4,355 |
| Genzyme Corporation Jul 24, 2025 | Consulting Fee WAYRILZ · Immunology | $2,016 |
| Genzyme Corporation Jul 17, 2025 | Compensation for services other than consulting (speaking, faculty) WAYRILZ · Immunology | $6,920 |
| Genzyme Corporation Jul 17, 2025 | Travel and Lodging WAYRILZ · Immunology · travel to Chattanooga, TN · in-kind | $890 |
| Genzyme Corporation Jul 8, 2025 | Compensation for services other than consulting (speaking, faculty) WAYRILZ · Immunology | $2,307 |
| Recordati_rare_diseases_inc. May 9, 2025 | Honoraria ENJAYMO · HEMATOLOGY | $5,880 |
| Recordati_rare_diseases_inc. May 9, 2025 | Travel and Lodging ENJAYMO · HEMATOLOGY · travel to NEWARK, NJ | $608 |
| Recordati_rare_diseases_inc. May 9, 2025 | Travel and Lodging ENJAYMO · HEMATOLOGY · travel to NEWARK, NJ | $193 |
| Recordati_rare_diseases_inc. May 9, 2025 | Travel and Lodging ENJAYMO · HEMATOLOGY · travel to NEWARK, NJ | $50.00 |
| Recordati_rare_diseases_inc. May 9, 2025 | Travel and Lodging ENJAYMO · HEMATOLOGY · travel to NEWARK, NJ | $35.00 |
| AstraZeneca Pharmaceuticals LP Apr 29, 2025 | Compensation for services other than consulting (speaking, faculty) IMFINZI · Oncology Company’s descriptionSpeaker Fee | $3,350 |
| AstraZeneca Pharmaceuticals LP Apr 28, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $2,680 |
| AstraZeneca Pharmaceuticals LP Apr 1, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $250 |
| Genzyme Corporation Feb 28, 2025 | Compensation for services other than consulting (speaking, faculty) WAYRILZ · Immunology | $1,318 |
| AstraZeneca Pharmaceuticals LP Feb 13, 2025 | Consulting Fee DATROWAY · Oncology | $670 |
| AstraZeneca Pharmaceuticals LP Jan 22, 2025 | Consulting Fee DATROWAY · Oncology | $2,010 |
| AstraZeneca Pharmaceuticals LP Jan 22, 2025 | Compensation for services other than consulting (speaking, faculty) IMFINZI · Oncology Company’s descriptionSpeaker Fee | $300 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 8 companies. The companies reported $369,999 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual…
AstraZeneca Pharmaceuticals LP - A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line T…
Janssen Research & Development, LLC - A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treat…
AstraZeneca Pharmaceuticals LP - A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment Wi…
Genmab A/s - A phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non …
AstraZeneca Pharmaceuticals LP - Cold Agglutinin Disease Real World Evidence Registry
Sanofi US Services Inc. · Active, not recruiting · NCT05791708 - A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase in…
AstraZeneca Pharmaceuticals LP - A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line T…
Janssen Research & Development, LLC - A Phase III,Open label,Randomised,Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations,and Whose …
AstraZeneca UK Limited - Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09)
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.